Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.

Thoennissen, Gabriela B; Görlich, Dennis; Bacher, Vera Ulrike; Aufenberg, Thomas; Hüsken, Anne-Christin; Hansmeier, Anna Antonia; Evers, Georg; Mikesch, Jan-Henrik; Fritz, Fleur; Bokemeyer, Carsten; Müller-Tidow, Carsten; Stelljes, Matthias; Mesters, Rolf M; Krug, Utz; Kropff, Martin H; Thoennissen, Nils H; Berdel, Wolfgang E (2017). Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. Acta haematologica, 137(3), pp. 163-172. Karger 10.1159/000463534

[img]
Preview
Text
VUB_Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction.pdf - Published Version
Available under License Publisher holds Copyright.

Download (214kB) | Preview

Within this retrospective single-center study, we analyzed the survival of 320 multiple myeloma (MM) patients receiving melphalan high-dose chemotherapy (HDCT) and either single (n = 286) or tandem (n = 34) autologous stem cell transplantation (ASCT) from 1996 to 2012. Additionally, the impact of novel induction regimens was assessed. Median follow-up was 67 months, median overall survival (OS) 62 months, median progression-free survival (PFS) 33 months (95% CI 27-39), and treatment-related death (TRD) 3%. Multivariate analysis revealed age ≥60 years (p = 0.03) and stage 3 according to the International Staging System (p = 0.006) as adverse risk factors regarding PFS. Median OS was significantly better in newly diagnosed MM patients receiving induction therapy with novel agents, e.g., bortezomib, thalidomide, or lenalidomide, compared with a traditional regimen (69 vs. 58 months; p = 0.01). More patients achieved at least a very good partial remission in the period from 2005 to 2012 than from 1996 to 2004 (65 vs. 30%; p < 0.001), with a longer median OS in the later period (71 vs. 52 months, p = 0.027). In conclusion, our analysis confirms HDCT-ASCT as an effective therapeutic strategy in an unselected large myeloma patient cohort with a low TRD rate and improved prognosis due to novel induction strategies.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Bacher, Vera Ulrike

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0001-5792

Publisher:

Karger

Language:

English

Submitter:

Katrin Kölliker-Schütz

Date Deposited:

06 Sep 2017 13:24

Last Modified:

01 May 2018 02:30

Publisher DOI:

10.1159/000463534

PubMed ID:

28399522

Uncontrolled Keywords:

Autologous stem cell transplantation Induction therapy  Melphalan high-dose chemotherapy Multiple myeloma  Novel compounds Tandem autologous stem cell transplantation

BORIS DOI:

10.7892/boris.100072

URI:

https://boris.unibe.ch/id/eprint/100072

Actions (login required)

Edit item Edit item
Provide Feedback